CervoMed
Boston, Massachusetts, United States · Biotechnology, Healthcare, Health Care
CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry.
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 17
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (CRVO)
- Website
- www.cervomed.com
- Company page
Recent activity at CervoMed
- : SEC 8-K (8.01): CervoMed Inc. reported on October 29, 2026, significant updates in its business regarding advances in Alzheimer's research and therapy related publications. The filing incorporates details from a press release specifically addressing new findings that may impact the company's direction and strategy in the field of neuroscience. While specific financial amounts were not disclosed, the implications of such research are expected to affect stakeholder interest and future funding opportunities. This report is part of the company's ongoing commitment to transparency regarding important developments that could impact shareholders.
- : SEC 8-K (7.01):
- : SEC 8-K (8.01): The filing pertains to the release of initial biomarker data from a Phase 2a study in nfvPPA, as mentioned in a press release issued by CervoMed Inc. on October 12, 2026. This announcement is significant for stakeholders as it could impact the company's strategic direction in developing treatments for neurodegenerative diseases. The filing references specific findings and insights that may influence future trials or collaborations. The event occurred very recently, within the specified timeframe, reinforcing its relevance and urgency.
- : SEC 8-K (7.01):
- : SEC 8-K (8.01): This filing concerns 'Other Events' as reported in a press release dated September 28, 2026, from CervoMed Inc. The press release includes important supporting data and details relevant to the company's recent activities. Although specific transaction details are not provided in this excerpt, it indicates ongoing communication to shareholders about significant events impacting the company. The inclusion of these details suggests strategic implications that may be critical to investors. Specific financial metrics or implications were not disclosed in this part of the filing.
- : SEC 8-K (8.01): On September 10, 2026, CervoMed Inc. announced via a press release that the initial results from their Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia have been accepted as a late-breaking oral presentation. This presentation is scheduled for the Annual Meeting of the International Society of Frontotemporal Dementias, taking place from October 8 to 11, 2026, in Philadelphia, Pennsylvania. This event highlights the company's ongoing research and may have strategic implications for their standing in the neurodegenerative disease research community.
- : SEC 8-K (8.01):
- : SEC 8-K (8.01): The 8-K filing reports significant findings related to Neflamapimod, specifically its treatment effects in 'Pure' DLB and the planned Phase 3 dose as discussed in the press release issued on July 14, 2026. The analyses reinforce the durable slowing of basal forebrain atrophy, indicating potential positive implications for treatment strategies. Additionally, the filing highlights new pharmacokinetic/pharmacodynamic analyses and Phase 2 study results that enhance the understanding of dosing for Neflamapimod at 80 mg BID in DLB. These updates suggest a positive trajectory for ongoing and future clinical trials, enhancing stakeholders' insights into the drug's efficacy and treatment applications.
- : SEC 8-K (8.01): CervoMed Inc. issued a press release on July 9, 2026, detailing the results of a recent publication in Nature Neuroscience, which supports the inhibition of p38α as a potential therapeutic approach for frontotemporal dementia (FTD). Additionally, the press release mentions that interim results from the Phase 2a clinical trial will be presented at the upcoming CTAD conference. This information could significantly influence investor sentiment and the company’s stock performance, highlighting ongoing research efforts and potential future therapeutic developments. The event date of the press release is critical as it addresses current advancements and clinical trials in the field.
- : SEC 8-K (7.01): On July 9, 2026, CervoMed Inc. announced the completion of enrollment in its Phase 2a study for neflamapimod, targeting nonfluent variant primary progressive aphasia, which is classified as a type of frontotemporal dementia (FTD). This phase of the study is critical in evaluating the drug's efficacy and safety for patients suffering from this condition. The completion of enrollment signifies a significant milestone in the clinical development of this therapeutic, aimed at addressing unmet medical needs in neurology. The announcement was made through a press release, indicating the company's ongoing commitment to advancing its research initiatives in the field of neurodegenerative diseases.
CervoMed funding history
| Date | Round | Amount |
|---|---|---|
| May 2020 | Seed | $750K |
| May 2020 | Seed | $625K |
| Dec 2019 | Seed | $783K |
| Jun 2019 | Pre-Seed | $164K |
| Mar 2017 | Venture | $15.8M |
Leadership
- David Kalergis, Executive Officer, Director
- John Gainer, Director
- Robert Adams, Director
- Mark Giles, Director
- Alan Levin, Director
- Robert Cobuzzi, Director
Verified email and direct lines for CervoMed’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
CervoMed in the news
- CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - Yahoo! Finance Canada (Jun 12, 2026)
- A rare dementia can take away speech; no drug is approved for it. CervoMed saw a nerve-damage marker fall over 12 weeks. - Stock Titan (Oct 12, 2026)
- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) - Yahoo Finance (Jul 14, 2026)
- CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) - The Manila Times (Oct 29, 2026)
- CervoMed Announces Completion of Merger with EIP Pharma - PR Newswire (Aug 16, 2023)
- CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - Yahoo Finance (Jun 18, 2026)
- CRVO | CervoMed Inc. Common Stock Analyst Forecasts - Quiver Quantitative (Mar 25, 2025)
- CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026 - Yahoo Finance (Oct 12, 2026)
Companies similar to CervoMed
- Sydnexis · Biotechnology, Healthcare, Health Care
- Damora Therapeutics, Inc. · Biotechnology, Healthcare, Health Care
- Omeza · Biotechnology, Healthcare, Health Care
- INVO Fertility, Inc. · Biotechnology, Healthcare, Health Care
- Kernal Biologics · Biotechnology, Healthcare, Health Care
About CervoMed: questions and answers
What does CervoMed do?
CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry.
Where is CervoMed headquartered?
CervoMed is headquartered in Boston, Massachusetts, United States.
How many employees does CervoMed have?
CervoMed has about 17 employees.
Has CervoMed raised funding?
Yes. Fundz has recorded 5 funding events for CervoMed. The most recent, Seed of $750K, was in May 2020.
What is the latest news on CervoMed?
On Oct 29, 2026, SEC 8-K (8.01): CervoMed Inc. reported on October 29, 2026, significant updates in its business regarding advances in Alzheimer's research and therapy related publications. The filing incorporates details from a press release specifically addressing new findings that may impact the company's directi
Is CervoMed a public company?
Yes. CervoMed is publicly traded under the ticker CRVO.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy